Please use this identifier to cite or link to this item: http://repository.i3l.ac.id/jspui/handle/123456789/141
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAlexandra, Hardiani-
dc.date.accessioned2021-10-22T06:48:56Z-
dc.date.available2021-10-22T06:48:56Z-
dc.date.issued2019-12-11-
dc.identifier.urihttp://repository.i3l.ac.id/jspui/handle/123456789/141-
dc.description.abstractAlzheimer’s Disease (AD) is the primary cause of Dementia, a clinical syndrome that is the leading cause of death in elderly individuals. Aging societies are currently racing to find potential treatment for AD that will not only alleviate the symptoms but also slows or reverse the disease’s progression as the risk of getting AD increases alongside with age. Interleukin 33 (IL-33) has been shown to be a promising potential AD treatment in a study conducted by Fu et al (2016). The purpose of this study is to follow-up the effect of long-term IL-33 treatment in APPswe/Psen1dE9 (APP/PS1) mice. Passive Avoidance task, Magnetic Resonance Imaging (MRI) analysis and Immunohistochemical staining were used in analyzing the effect of the treatment. Passive avoidance results showed that there was no improvement in memory retention in APP/PS1 mice that has been treated with IL-33. Moreover, the neuroimaging analysis showed an increase in total average grey matter volume in the APP/PS1 mice. The APP/PS1 IL-33 treated mice did have slightly lower GFAP and Iba1 the brain compared to the control counterpart. In conclusion, continuous injection of IL-33 treatment might be needed to maintain its beneficial effects in subjects with AD. + positive cells in subjects with AD.en_US
dc.language.isoenen_US
dc.publisherIndonesia International Institute for Life Sciencesen_US
dc.relation.ispartofseriesBM 19-001;T201912001-
dc.subjectAlzheimer’s Diseaseen_US
dc.subjectDementiaen_US
dc.subjectInterleukin 33en_US
dc.subjectAPPswe/Psen1dE9en_US
dc.subjectPassive avoidanceen_US
dc.subjectMRI analysisen_US
dc.subjectimmunohistochemical stainingen_US
dc.titlea Follow-up Study of App/PS1 Mice Treated With IL-33en_US
dc.typeThesisen_US
Appears in Collections:Biomedicine

Files in This Item:
File Description SizeFormat 
Hardiani Alexandra.pdf
  Restricted Access
Full text96.18 MBAdobe PDFView/Open Request a copy
Cover.pdfCover64.85 kBAdobe PDFView/Open
Abstract.pdfAbstract95.08 kBAdobe PDFView/Open
Chapter 1.pdfChapter 186.24 kBAdobe PDFView/Open
References.pdfReferences123.05 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.